CHEMOKINE RECEPTOR CXCR4 EXPRESSION AND MICROVESSELS DENSITY IN MALIGNANT TUMORS OF THE BREAST OF PATIENTS WITH SIGNS OF METABOLIC SYNDROME
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-1-2020-g.8612Keywords:
body mass index, breast cancer, CXCR4, metabolic syndrome, microvessel density, S18-2Abstract
Aim: to evaluate CXCR4, S18-2 expression and microvessel density (MVD) in malignant tumors of the breast of different molecular subtypes, depending on the presence in patients of such signs of metabolic syndrome (MS) as obesity and hypertension (AH). Object and methods: samples of surgical material and peripheral blood serum (PBS) for 65 breast cancer (ВС) patients (stage I–II) of the tumor process, with different molecular subtypes: luminal A (37 cases), luminal B (14 cases) and basal (10 cases). The average age of patients is 58.0 ± 1.9 years. Methods: clinical, morphological, immunohistochemical (IHC), enzyme-linked immunoaassay (ELISA), statistical. Results: the highest expression of the chemokine receptor CXCR4 and MVD was found in breast tumors with the molecular subtype luminal B (51.6 ± 4.2% and 13,5±2,3 vessels/mm2 respectively). For luminal A and basal subtypes, these indicators decreased: CXCR4 (49.9 ± 2.8% and 41.4 ± 4.0% respectively) and MVD (5,1 ± 1,3 vessels/mm2, p <0.05 and 8,0 ± 1,7 vessels/mm2 respectively). Increased expression of CXCR4 (55.8 ± 2.9%) and S18-2 (10.1 ± 1.1%) and MVD (8.0 ± 1.7 vessels mm2) was detected in the tumor tissue of the luminal A subtype of patients with signs MS compared to the expression of these parameters in tumors of patients without signs of MS (48.7 ± 2.4%, 5.2 ± 0.3%, p < 0.05 and 5.3 ± 1.8 vessels/mm2 respectively). Increased expression of CXCR4 (51.6 ± 2.8%) and S18-2 (11.9 ± 1.2%) and MVD (7.4 ± 2.0 vessels/mm2) were determined in tumors of ВС patients with cancer metastases compared with the values of these parameters in tumors of patients without metastases: 43.4 ± 2.3%; 4.6 ± 0.8%, p <0.05 and 5.3 ± 1.8 vessels/mm2 respectively. Conclusions: increased expression of the chemokine receptor CXCR4, mitochondrial ribosomal protein S18-2 and MVD in breast tumor cells is associated with both the molecular subtypes of breast cancer and the presence of obesity and hypertension in patients and is associated with the occurrence of patients with metastases, which may indicate the prognostic value of investigated markers for detectable markers the course of the disease.
References
Kazan M, Karalti I. The association between obesity and cancer. Endocrinol Metab Syndr 2015; 4 (4): 196. doi: 10.4172/2161-1017.1000196.
Laurent V, Guérard A, Mazerolles C, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun 2016; 7: 10230.
Donohoe CL, Lysaght J, O’Sullivan J, Reynolds JV. Emerging concepts linking obesity with the hallmarks of cancer. Trends Endocrinol Metab 2017; 28 (1): 46–62.
Anido S, Barone I, Giordano C, et al. The multifaceted mechanism of leptin signaling within tumor microenvironment in driving breast cancer growth and progression. Front Oncol 2014; 4: 340. doi 103389/fonc.2014.00340.
Nesina IP, Zadvorny TV, Nespryad’ko SV, et al. Сontents of adiponectin and leptin in peripheral blood serum of brest and endometrial cancer patients with obesity. Oncology 2019; 21 (1): 17–22 (In Ukrainian).
Boudot A, Kerdivel G, Habauzit D, et al. Differential еstrogen-regulation of CXCL12 сhemokine receptors, CXCR4 and CXCR7, contributes to the growth еffect of еstrogens in breast cancer cells. PLoS ONE 2011; 6 (6): e20898.
Sahoo SS, Zhang XD, Hondermarck H, Tanwar PS. The Emerging role of the microenvironment in endometrial cancer. Cancers 2018; 10: 408.
Sobolika T, Wellsc S Y-jun, Ayersd GD, et al. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Molecular Biology Cell M BoC 2014; 25 (5): 566–70.
GhoneumA, Afify H, Salih Z, et al. Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget 2018; 9 (32): 22832–49.
Huang K, Kiefer C, Kamal A. Novel role for NFAT3 in ERK-mediated regulation of CXCR4. PLoS One 2014; 9 (12): e115249.
Wu N, Yang Yi, Yu N, et al. Tetramethylpyrazine downregulates transcription of the CXC receptor 4 (CXCR4) via nuclear respiratory factor‑1 (Nrf‑1) in WERI‑Rb1 retinoblastoma cells. Oncology Reports 2019; 42 (3): 1214–24
Mushtaq M, Jensen L, Davidsson S, et al. MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells. Sci Rep 2018; 8 (1): 2268.
Buchynska LG, Iurchenko NP, Kashuba EV, et al. Оverexpression of the mitochondrial ribosomal protein S18-2 in the invasive breast carcinomas. Exp Oncol 2018; 40 (4): 303–8.
Yao L, Heuser-Baker J, Barlic-Dicen J. Chemokine receptors on the defensive — the surprising role of CXCR4 in brown adipose tissue. Receptors Clinical Investigation 2015; 2: e397.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of the female reproductive organs (IARC WHO Classification of tumours). 4th Ed: IARC 2014. 307 p.
Ayala NС, Alsina А, Pescie MМG, et al. CXCR4/SDF-1 expression in HER2/neu breast cancer biopsies and its relation to adjuvant treatment. J Clin Oncol 2016; 34(15). doi: 10.1200/JCO.2016.34.15_suppl.e12090.
Lefort S, Thuleau A, Kieffer Y, et al. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene 2017; 36: 1211–22.
Lang K, Ratke J. Leрptin and adiponectin: new players in the field of tumor cell and leukocyte migration. BMC 2009 (https://doi.org/10.1186/1478-811X-7-27).
Liu L, Wang L, Zheng J, Tang G. Leрptin promotes human endometrial carcinoma cell proliferation by enhancing aromatase (P450arom) expression and estradiol formation. E J Obstetrics Gynecoly Reproductive Biol 2013; 170 (1): 198–201.
Candelaria Pv, Rampoldi A, Harbuzariu A, Gonzalez-Perez RR. Leptin signaling and cancer chemoresistance: Perspectives. World J Clin Oncol 2017; 8 (2): 106–19.
